Free Trial
NASDAQ:KALA

KALA BIO (KALA) Stock Price, News & Analysis

KALA BIO logo
$3.75 +0.03 (+0.81%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$3.72 -0.03 (-0.80%)
As of 05/2/2025 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About KALA BIO Stock (NASDAQ:KALA)

Key Stats

Today's Range
$3.64
$3.94
50-Day Range
$2.94
$7.57
52-Week Range
$2.92
$11.20
Volume
38,020 shs
Average Volume
91,557 shs
Market Capitalization
$24.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Buy

Company Overview

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

KALA BIO Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

KALA MarketRank™: 

KALA BIO scored higher than 42% of companies evaluated by MarketBeat, and ranked 312th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    KALA BIO has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    KALA BIO has only been the subject of 1 research reports in the past 90 days.

  • Read more about KALA BIO's stock forecast and price target.
  • Earnings Growth

    Earnings for KALA BIO are expected to grow in the coming year, from ($10.84) to ($6.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of KALA BIO is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of KALA BIO is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    KALA BIO has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about KALA BIO's valuation and earnings.
  • Percentage of Shares Shorted

    5.32% of the float of KALA BIO has been sold short.
  • Short Interest Ratio / Days to Cover

    KALA BIO has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in KALA BIO has recently increased by 6.24%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    KALA BIO does not currently pay a dividend.

  • Dividend Growth

    KALA BIO does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.32% of the float of KALA BIO has been sold short.
  • Short Interest Ratio / Days to Cover

    KALA BIO has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in KALA BIO has recently increased by 6.24%, indicating that investor sentiment is decreasing significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, KALA BIO insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 8.32% of the stock of KALA BIO is held by insiders.

    • Percentage Held by Institutions

      Only 24.61% of the stock of KALA BIO is held by institutions.

    • Read more about KALA BIO's insider trading history.
    Receive KALA Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for KALA BIO and its competitors with MarketBeat's FREE daily newsletter.

    KALA Stock News Headlines

    Trump’s treachery
    Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
    Kala announces resignation of CEO Iwicki, Bazemore appointed interim CEO
    See More Headlines

    KALA Stock Analysis - Frequently Asked Questions

    KALA BIO's stock was trading at $6.94 at the beginning of the year. Since then, KALA shares have decreased by 46.0% and is now trading at $3.75.
    View the best growth stocks for 2025 here
    .

    KALA BIO, Inc. (NASDAQ:KALA) announced its earnings results on Friday, March, 28th. The company reported ($1.74) earnings per share for the quarter, beating the consensus estimate of ($2.28) by $0.54.

    KALA BIO shares reverse split on Friday, October 21st 2022. The 1-50 reverse split was announced on Friday, October 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

    KALA BIO (KALA) raised $90 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

    Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that KALA BIO investors own include Plug Power (PLUG), Ovid Therapeutics (OVID), Fortress Biotech (FBIO), FuelCell Energy (FCEL), Workhorse Group (WKHS), Lipocine (LPCN) and Comtech Telecommunications (CMTL).

    Company Calendar

    Last Earnings
    3/28/2025
    Today
    5/03/2025
    Next Earnings (Estimated)
    5/13/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:KALA
    Employees
    30
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $15.00
    High Stock Price Target
    $15.00
    Low Stock Price Target
    $15.00
    Potential Upside/Downside
    +300.0%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    2 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    $-42,200,000.00
    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    $3.89 million
    Price / Cash Flow
    N/A
    Book Value
    $2.79 per share
    Price / Book
    1.34

    Miscellaneous

    Free Float
    5,584,000
    Market Cap
    $24.20 million
    Optionable
    Not Optionable
    Beta
    -1.91

    Social Links

    Investing Strategies To Help Grow Your Retirement Income Cover

    Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

    Get This Free Report

    This page (NASDAQ:KALA) was last updated on 5/3/2025 by MarketBeat.com Staff
    From Our Partners